Avadel Pharmaceuticals (AVDL)
8.03
-0.09 (-1.11%)
At close: Mar 28, 2025, 3:59 PM
8.15
1.56%
After-hours: Mar 28, 2025, 06:23 PM EDT
Company Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.
Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Avadel Pharmaceuticals
| Country | IE |
| IPO Date | Jun 7, 1996 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 188 |
| CEO | Gregory J. Divis Jr. |
Contact Details
Address: 10 Earlsfort Terrace Dublin, IE | |
| Website | https://www.avadel.com |
Stock Details
| Ticker Symbol | AVDL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001012477 |
| CUSIP Number | 05337M104 |
| ISIN Number | US05337M1045 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory J. Divis Jr. | Chief Executive Officer & Director |
| Thomas S. McHugh | Senior Vice President, Principal Financial & Accounting Officer and Chief Financial Officer |
| Angie Woods | Vice President of People & Culture |
| Dr. Jason M. Vaughn | Senior Vice President of Technical Operations |
| Dr. Jordan S. Dubow M.D. | Consultant |
| Gregory J. Davis | Vice President of Corporate and Business Development |
| Jennifer Gudeman PharmD | Senior Vice President of Medical & Clinical Affairs |
| Jerad G. Seurer | General Counsel, Company Secretary & Compliance Officer |
| Mark W. Elrod | Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 07, 2025 | 8-K | Current Report |
| Mar 07, 2025 | 4 | Filing |
| Mar 07, 2025 | 4 | Filing |
| Mar 07, 2025 | 4 | Filing |
| Mar 03, 2025 | 10-K | Annual Report |
| Mar 03, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 28, 2025 | 4 | Filing |
| Jan 22, 2025 | 4 | Filing |
| Jan 14, 2025 | 4 | Filing |